20
Participants
Start Date
January 31, 2009
Primary Completion Date
September 7, 2015
Study Completion Date
September 7, 2015
Eltrombopag
The 10 subjects will be treated with eltrombopag 75 mg once daily. Patients will be monitored 3 times, weekly, for the first 2 weeks, and then monitored as clinically indicated as they continue eltrombopag dosing for 3-4 months.
Romiplostim
three of the patients treated with eltrombopag will be treated with weekly romiplostim at a dose of 10 micrograms/kg weekly for 2 weeks with testing at weekly intervals for 3 times
healthy controls
single blood draw for all measures included in the intervention arms
Weill Cornell Medical College, New York
Collaborators (1)
GlaxoSmithKline
INDUSTRY
Weill Medical College of Cornell University
OTHER